alexa ATP Metabolism as Biomarker Target for Cardiovascular Protection | OMICS International
ISSN: 2329-6607
Cardiovascular Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

ATP Metabolism as Biomarker Target for Cardiovascular Protection

Pollen K Yeung*

Dalhousie University, Canada

*Corresponding Author:
Pollen K Yeung
Dalhousie University
Halifax, NS, Canada
Tel: 902-494-3845
Fax: 902-494-1396
E-mail: [email protected]

Received date: August 29, 2013; Accepted date: August 29, 2013; Published date: September 04, 2013

Citation: Yeung PK (2013) ATP Metabolism as Biomarker Target for Cardiovascular Protection. Cardiol Pharmacol 2:e118. doi:10.4172/2329-6607.1000e118

Copyright: © 2013 Yeung PK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Cardiovascular Pharmacology: Open Access

Cardiovascular disease including stroke is the leading cause of death and disability worldwide and an enormous economic burden to our societies [1]. Based on the latest statistics released for heart and stroke disease, an estimated 83,600,000 adults in the United States (US) (>30%) have one or more types of Cardiovascular Disease (CVD) of whom more than 90% have hypertension, 18% have Coronary Heart Disease (CHD), close to 10% have Myocardial Infarction (MI) and 8% have stroke. The total direct and indirect cost in the US alone for treatment of cardiovascular diseases (hospitalization, drugs, home healthcare, etc.) and lost of productivity and morbidity is estimated at close to $315 billion US per year [2]. Thus prevention by better diagnosis and drug treatment could provide a huge saving for the health care cost worldwide. Despite advancement in modern cardiovascular medicine, the prevalence of hypertension, Ischemic Heart Disease (IHD) and stroke is still on the rise, and that finding an optimum therapy to slow disease progression remains a therapeutic challenge.

In our laboratory, we have been embarking on the concept to study the potential of circulatory concentrations of adenosine and ATP and their metabolites as biomarkers for cardiovascular protection and as targets for anti-ischemia drugs [3,4]. The importance of adenosine and ATP in regulating many biological functions has long been recognized, especially for their effects on the cardiovascular system [5,6]. It is known that adenosine and ATP are key factors in regulation of coronary blood flow [7], inhibiting platelet aggregation [8], protection of myocardium [9], neuromodulation [10], attenuating tissue necrosis [6], ischemic preconditioning [11], immunomodulation [12], energy metabolism [13], and pain mediation [14] which together maintain the homeostasis of the cardiovascular system. It has been shown that patients with effort angina and essential hypertension have altered adenosine metabolism compared to healthy individuals [15], and that plasma concentration of adenosine increase in patients with Congestive Heart Failure (CHF) [16], which could be a physiologic response to heart failure and help to reduce the severity of the disease [17]. Thus it has been postulated that adenosine and ATP may be used as sensitive biomarkers to quantify myocardial and endothelial ischemia [18], and for monitoring therapeutic effects of anti-ischemia drugs [19,20].

In response to ischemia, ATP is broken down to release adenosine. The activity of adenosine is very short lived because it is rapidly taken up by myocardial and endothelial cells, erythrocytes (RBC), and also rapidly metabolized to inosine and subsequently to hypoxanthine, adenine, S-Adenosyl Homocysteine (SAH), and other adenine nucleotides [15]. There are also evidences to indicate that ATP is a neurotransmitter and released together with adenosine to maintain the homeostasis within the cardiovascular system and for neuroprotection [21]. Extracellular ATP is broken down rapidly to ADP and AMP and finally to adenosine by 5’-nucleotidase [15]. These metabolic events are known to occur in the myocardium as well as in erythrocytes (RBC), but it is not clear whether or not they are regulated by similar mechanism [22,23].

There is a host of evidence to indicate that many clinically useful therapeutic agents act by altering the normal physiologic functions of adenosine [24]. For example, dipyridamole exerts its vasodilating effect by inhibiting the uptake of endogenous adenosine thereby prolonging its effect in the circulation [25,26]. On the other hand, theophylline and the methylxanthines are competitive inhibitors of adenosine binding to its receptors and hence they antagonize the effects of adenosine and dipyridamole [24]. Adenosine and ATP and their association with energy metabolism are increasingly exploited as targets for drug discovery and development for a wide variety of clinical conditions [27]. For example, adenosine A2A receptor agonists are currently developed as anti-inflammatory agents or for stress test [28], the P2Y12 receptor antagonists for coronary artery disease [29], and the A1 receptor agonists and P2X7 antagonists have potential for cardiovascular and neuroprotection [30]. There are now also evidences both from our laboratory and others to indicate that while many cardiovascular drugs such as nucleoside transport inhibitors, calcium antagonists (CCBs), sotalol, and amiodarone inhibit the uptake of adenosine, others such as propranolol and enalapril are practically devoid of any inhibitory activity [19,31]. Thus adenosine and ATP transport and metabolism are clinically relevant therapeutic targets for cardiovascular and neuroprotective agents [30,32,33].

In summary, ATP and adenosine metabolism are key regulators affecting cardiovascular homeostasis. They could be exploited as biomarker targets for drug development and management of cardiovascular diseases which have affected millions of patients worldwide.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 24th Annual Cardiologists Conference
    June 11-13, 2018 Barcelona, Spain
  • 3rd International Conference on Cardiovascular Medicine and Cardiac Surgery
    July 05-06, 2018 Berlin, Germany
  • 25th Annual Congress on Cardiology and Medical Interventions
    July 16-17, 2018 Atlanta, USA
  • 6th Global Experts Meeting on Cardiology and Cardiovascular Pharmacology
    September 24-25, 2018 Tokyo, Japan
  • Current and Future trends in Cardio Vascular Diseases: Research and Outcomes
    October 05-06, 2018 Los Angeles, USA

Article Usage

  • Total views: 12143
  • [From(publication date):
    December-2013 - May 21, 2018]
  • Breakdown by view type
  • HTML page views : 8312
  • PDF downloads : 3831
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7